Cargando…
A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
PURPOSE: This research article assesses the cardiovascular impact of long-term injectable antipsychotic therapy on patients diagnosed with schizophrenia spectrum disorders. In our study, we attempted to quantify the potential causes of cardiovascular damage, assess cardiovascular parameters, and cor...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354682/ https://www.ncbi.nlm.nih.gov/pubmed/30774346 http://dx.doi.org/10.2147/NDT.S186892 |
_version_ | 1783391217161076736 |
---|---|
author | Andor, Minodora Dehelean, Liana Romosan, Ana-Maria Buda, Valentina Radu, Gabriela Caruntu, Florina Bordejevic, Aurora Manea, Minodora Marinela Papava, Ion Bredicean, Cristina Ana Romosan, Radu Stefan Tomescu, Mirela |
author_facet | Andor, Minodora Dehelean, Liana Romosan, Ana-Maria Buda, Valentina Radu, Gabriela Caruntu, Florina Bordejevic, Aurora Manea, Minodora Marinela Papava, Ion Bredicean, Cristina Ana Romosan, Radu Stefan Tomescu, Mirela |
author_sort | Andor, Minodora |
collection | PubMed |
description | PURPOSE: This research article assesses the cardiovascular impact of long-term injectable antipsychotic therapy on patients diagnosed with schizophrenia spectrum disorders. In our study, we attempted to quantify the potential causes of cardiovascular damage, assess cardiovascular parameters, and correlate them with the time elapsed from the onset of the psychosis until the initiation of injectable antipsychotic therapy, as well as the duration of long-acting therapy, and finally, to compare two of the most utilized long-acting injectable (LAI) medications (olanzapine vs risperidone). PATIENTS AND METHODS: This cross-sectional study recruited 64 patients of 2 outpatient clinics undergoing treatment with LAI antipsychotics for schizophrenic spectrum disorder. The study reports outpatients’ clinical data, laboratory blood sample findings, routine echocardiography, as well as speckle tracking echocardiography. RESULTS: Among patients with longer durations of pre-long-acting antipsychotic treatment, body mass indices, mitral velocity wave values (E and A waves), and the global longitudinal strain (GLS) measurements significantly correlated with patients’ myocardial contractility. The study also found that GLS was significantly lower in the group in which pre-LAI duration was prolonged, and was not influenced by the duration of LAI treatment. Furthermore, patients receiving olanzapine showed significantly improved myocardial contractility as measured by the aforementioned parameters, in comparison with patients treated with risperidone. CONCLUSION: The results of our study indicate that patients suffering from schizophrenia and who are left untreated or poorly treated for a longer period of time may develop myocardial impairment. The changes may be both secondary to a high prevalence of cardiovascular risk factors and may also be generated by the disease per se. The group who received olanzapine demonstrated improved results for a longer period of time without proper medication. |
format | Online Article Text |
id | pubmed-6354682 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63546822019-02-15 A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication Andor, Minodora Dehelean, Liana Romosan, Ana-Maria Buda, Valentina Radu, Gabriela Caruntu, Florina Bordejevic, Aurora Manea, Minodora Marinela Papava, Ion Bredicean, Cristina Ana Romosan, Radu Stefan Tomescu, Mirela Neuropsychiatr Dis Treat Original Research PURPOSE: This research article assesses the cardiovascular impact of long-term injectable antipsychotic therapy on patients diagnosed with schizophrenia spectrum disorders. In our study, we attempted to quantify the potential causes of cardiovascular damage, assess cardiovascular parameters, and correlate them with the time elapsed from the onset of the psychosis until the initiation of injectable antipsychotic therapy, as well as the duration of long-acting therapy, and finally, to compare two of the most utilized long-acting injectable (LAI) medications (olanzapine vs risperidone). PATIENTS AND METHODS: This cross-sectional study recruited 64 patients of 2 outpatient clinics undergoing treatment with LAI antipsychotics for schizophrenic spectrum disorder. The study reports outpatients’ clinical data, laboratory blood sample findings, routine echocardiography, as well as speckle tracking echocardiography. RESULTS: Among patients with longer durations of pre-long-acting antipsychotic treatment, body mass indices, mitral velocity wave values (E and A waves), and the global longitudinal strain (GLS) measurements significantly correlated with patients’ myocardial contractility. The study also found that GLS was significantly lower in the group in which pre-LAI duration was prolonged, and was not influenced by the duration of LAI treatment. Furthermore, patients receiving olanzapine showed significantly improved myocardial contractility as measured by the aforementioned parameters, in comparison with patients treated with risperidone. CONCLUSION: The results of our study indicate that patients suffering from schizophrenia and who are left untreated or poorly treated for a longer period of time may develop myocardial impairment. The changes may be both secondary to a high prevalence of cardiovascular risk factors and may also be generated by the disease per se. The group who received olanzapine demonstrated improved results for a longer period of time without proper medication. Dove Medical Press 2019-01-25 /pmc/articles/PMC6354682/ /pubmed/30774346 http://dx.doi.org/10.2147/NDT.S186892 Text en © 2019 Andor et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Andor, Minodora Dehelean, Liana Romosan, Ana-Maria Buda, Valentina Radu, Gabriela Caruntu, Florina Bordejevic, Aurora Manea, Minodora Marinela Papava, Ion Bredicean, Cristina Ana Romosan, Radu Stefan Tomescu, Mirela A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication |
title | A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication |
title_full | A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication |
title_fullStr | A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication |
title_full_unstemmed | A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication |
title_short | A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication |
title_sort | novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354682/ https://www.ncbi.nlm.nih.gov/pubmed/30774346 http://dx.doi.org/10.2147/NDT.S186892 |
work_keys_str_mv | AT andorminodora anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT deheleanliana anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT romosananamaria anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT budavalentina anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT radugabriela anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT caruntuflorina anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT bordejevicaurora anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT maneaminodoramarinela anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT papavaion anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT brediceancristinaana anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT romosanradustefan anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT tomescumirela anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT andorminodora novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT deheleanliana novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT romosananamaria novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT budavalentina novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT radugabriela novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT caruntuflorina novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT bordejevicaurora novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT maneaminodoramarinela novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT papavaion novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT brediceancristinaana novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT romosanradustefan novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT tomescumirela novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication |